5 ways insurance shapes access to GLP-1 weight-loss drugs in 2026

What happened: Insurance coverage for GLP-1 weight-loss drugs such as Wegovy and Zepbound shapes who can afford them in 2026, spanning employer plans, Medicare rules, Medicaid, and out-of-pocket payment. Why it matters: Access to these drugs depends on coverage decisions across employer plans, Medicare, and Medicaid, with paying out of pocket as the remaining route. Key numbers: 2026

Insurance coverage for GLP-1 weight-loss drugs such as Wegovy and Zepbound shapes who can afford them in 2026, spanning employer plans, Medicare rules, Medicaid, and out-of-pocket payment.

Access to these drugs depends on coverage decisions across employer plans, Medicare, and Medicaid, with paying out of pocket as the remaining route. Key numbers: 2026